Based on our sequencing data, CCND1 amplification and CDKN2A loss are common mutation signatures for NPC tumor; and we have demonstrated that PAL is an effective drug targeting cell cycle to suppress tumor growth in NPC PDX model with CCND1 and CDKN2A CNV background. The gene discussed is CDKN2A; the disease is neoplasm.